{"id":"W2979509136","doi":"10.1182/blood.v118.21.955.955","title":"Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Brentuximab vedotin; ABVD; Medicine; Internal medicine; Oncology; Dacarbazine; Regimen; Chemotherapy regimen; Hodgkin's lymphoma; Chemotherapy; Surgery; Lymphoma; CD30; Vincristine; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005868884,0.000406212,0.001079923,0.0002933208,0.0002647343,0.0004977688,0.0003296417,0.0003648065,0.001074088],"category_scores_gemma":[0.0005406762,0.0002203121,0.0004224078,0.0002856457,0.0002505085,0.0003942651,0.0002417702,0.0009767606,0.0002218119],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000553987,"about_ca_system_score_gemma":0.0004700545,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005521741,"about_ca_topic_score_gemma":0.00179964,"domain_scores_codex":[0.9997978,0.00007442757,0.00001496908,0.00003917792,0.00003201881,0.00004151496],"domain_scores_gemma":[0.9995347,0.00009682731,0.0000793678,0.00002414006,0.00002060399,0.0002443223],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2992972,0.02575191,0.1978388,0.001231644,0.001797086,0.002378834,0.0007433601,0.004119864,0.07752951,0.0002794654,0.006117768,0.3829147],"study_design_scores_gemma":[0.09954973,0.4955026,0.3725084,0.0001944518,0.001353397,0.003151898,0.0002058415,0.005754827,0.01056497,0.0002525004,0.01090319,0.00005818591],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962345,0.002160238,0.0001861326,0.0001172903,0.00005052807,0.0001854264,0.0001757993,0.00002781514,0.0008623099],"genre_scores_gemma":[0.9980932,0.0007035885,0.0003055269,0.0001538897,0.00006435857,0.00008799525,0.0003155911,0.000002946801,0.0002729323],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001079923,"threshold_uncertainty_score":0.004019439,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01313755399026489,"score_gpt":0.2169617183832874,"score_spread":0.2038241643930225,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}